Odyssey Therapeutics, Inc. (ODTX)
Health Care · Clinical-stage biotechnology · Nasdaq
Clinical-stage biotech developing novel therapeutic candidates OD-001 and OD-002 with no approved products or revenue.
What Odyssey Therapeutics, Inc. does
Odyssey Therapeutics is a clinical-stage biotechnology company focused on developing novel product candidates through preclinical research and clinical trials. The company's lead programs include OD-001 (currently in phase 2a clinical trial) and OD-002 (in IND-enabling studies). The company has no approved products, has never generated revenue from product sales, and relies on capital raises to fund its drug development operations.
Themes: ["Clinical-stage drug development"]
Fundamentals
- Price$16.69 as of 2026-07-10 close
- Market cap$802M as of 2026-07-13
- 1-year return+1.6% as of 2026-07-10 close
- Net margin-3822.7% as of 2026-07-13
- ROE-69.0% as of 2026-07-13
- Debt / equity0.00 as of 2026-07-13
- Revenue growth (YoY)-19.0% as of 2026-07-13
- Beta0.83 as of 2026-07-13
Key risks (from latest filing)
["Clinical-stage company with no approved products and no product revenue; may never achieve profitability or successfully complete clinical development and regulatory approval"]
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.